Sanders Rebecca A, Moeschler Susan M, Gazelka Halena M, Lamer Tim J, Wang Zhen, Qu Wenchun, Hoelzer Bryan C
Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota, U.S.A.
Department of Anesthesiology Pain Division, Mayo Clinic, Rochester, Minnesota, U.S.A.
Pain Pract. 2016 Sep;16(7):899-904. doi: 10.1111/papr.12340. Epub 2015 Aug 27.
Spinal cord stimulators (SCS) are used to treat various chronic pain states. Establishing patient outcomes in terms of pain control, opioid medication use, and overall satisfaction is vital in maintaining SCS's role in clinical practice.
All patients who underwent SCS implantation between January 2001 and December 2011 at a tertiary academic pain medicine center were included if he or she underwent permanent cervical or thoracolumbar dorsal column SCS implantation and age was 18 or greater. For the 199 patients who met inclusion criteria, data were collected retrospectively. Preimplant information included indication for implantation, Numeric Rating Scale (NRS) score, and dose in oral morphine equivalents (OME). Postimplant NRS score was recorded at 6 months and 1 year. OME requirement and patient satisfaction were determined at 1 year postimplantation.
This data set showed an overall decrease in OME requirements and NRS scores at both 6 months and 1 year. These differences were statistically significant (P < 0.01) compared to preimplantation values. Additionally, 84.27% of patients were satisfied with their implants at 1 year. Patient outcomes were analyzed further in respect to implant indication; groups included failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), angina, and other. For all groups, there were statistically significant (P < 0.01) decreases in NRS scores at 6 months and 1 year. In the FBSS and CRPS groups, statistically significant (P < 0.02) decreases in OME usage existed.
Retrospective review of patients with spinal cord stimulators revealed OME reduction at 1 year for those patients in the FBSS and CRPS groups; patient satisfaction at 1 year and NRS score reduction at 6 months and 1 year were statistically significant for all groups.
脊髓刺激器(SCS)用于治疗各种慢性疼痛状态。在疼痛控制、阿片类药物使用和总体满意度方面确定患者的治疗效果对于维持SCS在临床实践中的作用至关重要。
纳入2001年1月至2011年12月在一家三级学术疼痛医学中心接受SCS植入的所有患者,条件为接受永久性颈段或胸腰段背柱SCS植入且年龄在18岁及以上。对于符合纳入标准的199例患者,进行回顾性数据收集。植入前信息包括植入指征、数字评分量表(NRS)评分以及口服吗啡当量(OME)剂量。植入后6个月和1年记录NRS评分。植入后1年确定OME需求和患者满意度。
该数据集显示,在6个月和1年时,OME需求和NRS评分总体均有所下降。与植入前值相比,这些差异具有统计学意义(P < 0.01)。此外,84.27%的患者在1年时对其植入物感到满意。根据植入指征对患者治疗效果进行了进一步分析;分组包括腰椎手术失败综合征(FBSS)、复杂性区域疼痛综合征(CRPS)、心绞痛及其他。对于所有组,在6个月和1年时NRS评分均有统计学意义的下降(P < 0.01)。在FBSS和CRPS组中,OME使用量有统计学意义的下降(P < 0.02)。
对脊髓刺激器患者的回顾性研究显示,FBSS和CRPS组患者在1年时OME用量减少;所有组在1年时的患者满意度以及在6个月和1年时NRS评分的降低均具有统计学意义。